By E. Janene Geiss
Philadelphia, Dec. 7 - Oculir, Inc. said it raised $7.3 million in series A preferred stock.
Onset Ventures and CHL Medical Partners were the lead investors. Other investors included Canaan Partners, Three Arch Partners, Shepherd Ventures and Windamere Venture Partners.
The financing will be used to continue development of the company's novel, non-invasive glucose testing product and to perform human clinical trials, company officials said in a news release.
As part of the financing, Leslie Bottorff of Onset Ventures and Myles Greenberg of CHL Medical will be joined by Wende Hutton of Canaan, Scott Glenn of Windamere, company chairman Michael Walsh and founder John Burd on the board of directors.
"Since its initial seed funding two years ago, Oculir has developed and demonstrated an innovative product concept that has the potential to provide significant benefits to the large population of people with diabetes. This type of innovation represents exactly what we seek for companies in our portfolio," Bottorff said in the release.
Oculir is a San Diego medical device company developing a non-invasive glucose testing system for people with diabetes.
| Issuer: | Oculir, Inc.
|
| Issue: | Series A preferred stock
|
| Amount: | $7.3 million
|
| Investors: | Onset Ventures, CHL Medical Partners (leads), Canaan Partners, Three Arch Partners, Shepherd Ventures, Windamere Venture Partners
|
| Announcement date: | Dec. 7
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
